Rani Therapeutics Holdings, Inc. Class A
As of Oct 22, 2026, Rani Therapeutics Holdings is in Stage 4, the downtrend phase, now in its first week (since Oct 19, 2026). It closed at $0.59, 76.5% below its 52-week high and below its 200-day average, which is falling.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is RANI early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
RANI among Biotechnology473rd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …473 | RANI | Stage 4 · wk 1 | 11 | −23.3% |
Rani Therapeutics Holdings: quick answers
What stage is Rani Therapeutics Holdings in?
As of Oct 22, 2026, Rani Therapeutics Holdings (RANI) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 19, 2026 and is in its first week there. What the four stages mean
Is Rani Therapeutics Holdings in an uptrend?
No. Rani Therapeutics Holdings is in a Stage 4 downtrend. It trades 38.6% below its 200-day average, which is falling.
How far is Rani Therapeutics Holdings from its 52-week high?
Rani Therapeutics Holdings closed at $0.59 on Oct 22, 2026, 76.5% below its 52-week high of $2.50. Its 52-week low is $0.59.
How has Rani Therapeutics Holdings performed over the past year?
As of Oct 22, 2026, Rani Therapeutics Holdings is down 79.4% over the past year and down 56.8% so far in 2026.
Which sector and industry is Rani Therapeutics Holdings in?
Rani Therapeutics Holdings is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.